OmniAb, Inc. is an antibody discovery company that licenses technology to pharmaceutical and biotech firms and academic institutions to identify next-generation therapeutics. The company’s platform utilizes proprietary transgenic animals, including OmniRat, OmniChicken, OmniMouse, and OmniTaur, to generate diverse antibody repertoires with human sequences. It offers services for discovering fully human antibodies, bispecific antibodies, single-domain antibodies, and peptides, leveraging in vivo affinity maturation and high-throughput screening. OmniAb integrates these biological tools with OmniDeep, a suite of artificial intelligence and machine learning tools for therapeutic optimization, and OmniHub, a bioinformatics portal for data visualization. The company serves partners in therapeutic areas such as oncology, immunology, and neurodegeneration, supporting the development of antibody-drug conjugates, CAR-T therapies, and targeted radiotherapeutics. Its business model includes upfront fees, service revenue, milestones, and royalties on commercial sales.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage omniab.com
Sector Healthcare IR page investors.omniab.com/overview/default.aspx
Tags
antibody discovery, transgenic animals, biologics, drug discovery, bioinformatics, peptide discovery, bispecific antibodies, single-domain antibodies, oncology, immunology, OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, OmniTaur, OmnidAb, OmniUltra, picobodies, OmniDeep, OmniHub, OmniTides
Press page —

Metrics

Valuation  
Market cap $ 723.444M
Market cap (USD) $ 723.444M
P/E -14.59
PEG —
P/BV 2.90
P/S 17.99
P/OCF 271.36
P/FCF 303.97
Dividend yield —
Turnover / mcap —
Returns  
ROE -23.4%
ROI -25.1%
ROIC -20.1%
Profit margin -347.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 26
Quality score -87.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2020
Revenue 18.666M 26.391M 34.164M 59.077M 0
Net profit -64.779M -62.033M -50.619M -22.334M 0
Free cash flow -37.02M -41.539M 703K -20.755M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2020
Share price 1.85 3.54 6.17 3.6 —
Price performance 12m -0.48 -0.43 0.71 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 21.1M 30.3M 3.84M 5.27M 7.39M
↳ YoY growth +43.3% -87.3% +37.1% +40.2%
Lease liabilities (USD) — 13.9M 25.8M 25.6M 23.2M 20.3M
Cash and deposits (USD) 0.00 189,971 33.4M 16.4M 27.6M 25.5M
Intangible assets (USD) — 176M 167M 155M 138M 125M
Right-of-use assets (USD) — 13.3M 21.5M 19.9M 17.8M 15.5M
Cash flow detail
Operating cash flow (USD) — -1.14M -3.59M 2.35M -39.7M -36.5M
Purchases of property, plant and equipment (USD) — -4.07M -17.2M -1.64M -1.88M -565,000
Change in receivables (cash effect) (USD) — 6.02M -12.7M 26.9M -625,000 189,000
Change in payables (cash effect) (USD) — 1.51M 15.1M 936,000 -2.41M -231,000
Income taxes paid (cash effect) (USD) — — 0.00 -2.61M -16,000 —
Share-based compensation (USD) — 15.1M 18.3M 24.8M 21.5M 15.8M
Operating cash flow before change in receivables (USD) — -11.7M 9.15M -24.6M -39M -36.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -9.74M -20.8M 703,000 -41.5M -37M
Income detail
Research and development expense (USD) — 39.2M 48.4M 56.5M 55.1M 47.8M
Total comprehensive income (USD) — -27M -22.3M -50.6M -62.1M -64.8M
Comprehensive income to owners (USD) — -27M -22.3M -50.6M -62.1M -64.8M
Reported Mar 30, 2023 Mar 30, 2023 Mar 25, 2024 Mar 25, 2024 Mar 18, 2025 Mar 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Conference Call to Begin Today at 8:00 a.m. ET

EMERYVILLE, Calif. (October 30, 2026) – OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and nine months ended September 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance.

“Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders within an efficient business model built on highly differentiated technologies,” stated Matt Foehr, Chief Executive Officer of OmniAb. “In addition, the expanded commercial launch of xPloration®, the introduction of OmniTides™, and continued progress across our portfolio of milestone- and royalty-bearing partnered programs reinforce our confidence in the durability of our revenue base and our long-term growth potential.

10/26/2026

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management’s participation in the following upcoming investor conferences:

**Stifel Healthcare Conference
**Date: Wednesday, November 11, 2026

**2026 Truist Securities BioPharma Symposium
**Date: Thursday, November 12, 2026

**Jefferies London Healthcare Conference
**Date: November 16–19, 2026

**Craig-Hallum Investor Conference
**Date: Tuesday, November 17, 2026

The Stifel Healthcare Conference, Truist Securities BioPharma Symposium, and Craig-Hallum Investor Conference will take place in New York City. The Jefferies London Healthcare Conference will take place in London, UK.

Management will be available for one-on-one meetings with investors at each conference. Interested investors should contact the conference organizers or email investor relations .

**About OmniAb
**OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. These technologies paired with xPloration, our AI-powered high-throughput single B-cell screening platform, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.

10/14/2026

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time.

Conference Call and Webcast

What: OmniAb conference call to discuss third quarter 2026 financial results and business updates
Date: Friday, October 30, 2026
Time: 8:00 a.m. Eastern time (5:00 a.m. Pacific time)
Phone: U.S. (833) 461-5787
International (585) 542-9983
Conference ID is 357 845 940
Webcast: Live and replay webcast of the call with slides will be available here.

About OmniAb®

OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. These technologies paired with xPloration, our AI-powered high-throughput single B-cell screening platform, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.

Prompts

OmniAb, Inc. (ticker OABI), listed in United States.

Company History

Date Change Detail
Nov 3, 2022 Renamed AVISTA PUBLIC ACQUISITION CORP. II → OMNIAB, INC.

ETFs Holding OmniAb, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.02% 148,300 $ 725.187K Nov 16, 2026
FESM 0.01% 187,291 $ 460.736K Jun 30, 2026
DFAS 0.01% 342,920 $ 1.697M Nov 12, 2026
DFSU 0.00% 10,686 $ 52.896K Nov 12, 2026
DCOR 0.00% 159,493 $ 789.49K Nov 12, 2026
DFAC 0.00% 217,764 $ 1.078M Nov 12, 2026
DXUV 0.00% 14,031 $ 69.453K Nov 12, 2026
DFAU 0.00% 22,797 $ 112.845K Nov 12, 2026
DFUS 0.00% 14,264 $ 70.607K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
OABI canonical Common share — US nasdaq 4.96 USD 2026-09-30
OABIW Warrant — US nasdaq 0.33 USD 2026-09-30